Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women
Status:
Completed
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
This randomized clinical trial will evaluate the efficacy of an antiresorptive osteoporosis
drug (denosumab) in prevention of periprosthetic bone loss and in promotion of implant
osseointegration (bone bonding) in postmenopausal women after total hip replacement. The
investigators assume that denosumab prevents periprosthetic bone loss and enhances bone
bonding of the hip stem in postmenopausal women.